SNMMI

Molecular Imaging Suggests Long-COVID Symptoms may be Caused by Fatigue
November 1, 2021 — Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than pathological changes in the brain, according to…
FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer
June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body.
New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge
June 16, 2021 — A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of…
SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients
June 16, 2021 — The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET), according to…
New Super-resolution Technique Allows for More Detailed Brain Imaging
June 14, 2021 — A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease — at their earliest stages, enabling physicians to diagnose…

18F-FDG PET in patients with long-COVID syndrome. A and B: Transaxial sections of group averaged, spatially normalized 18F-FDG PET scans in patients with long-COVID syndrome (A) and control patients (B). C: The pattern expression score (PES; *adjusted for age and sex, for illustration purposes) of the previously established COVID-19-related spatial covariance pattern was not significantly different between patients with long-COVID syndrome and control patients. Boxplots (grey), as well as individual values

News | Coronavirus (COVID-19)

Molecular Imaging Suggests Long-COVID Symptoms may be Caused by Fatigue

November 1, 2021 — Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than ...

November 01, 2021

Determination of ER status of disease. In 59-y-old woman diagnosed with ER-positive lobular BC 2 y previously and treated with tamoxifen, ER-positive bone metastases were identified 1 y after initial diagnosis.

News | Breast Imaging

Newly Approved PET Imaging Agent Solves Clinical Dilemmas in Breast Cancer Patients

October 4, 2021 — A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for ...

October 04, 2021

Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond

Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)

5 Strategies for Improving Your Nuclear Radiology Lab

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

September 16, 2021

The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R. 4479, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021” by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).

News | Nuclear Imaging

Council on Radionuclides and Radiopharmaceuticals Supports the FIND Act of 2021

August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient ...

August 04, 2021

A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality. Given the long axial field of view (AFOV) of the uEXPLORER, study authors have proposed new, extended measurements for phantoms to characterize total-body PET imaging more appropriately. This research was published in the June issue of The Journal of Nuclear Medicine.

News | PET Imaging

Total-body PET Imaging Exceeds Industry Standards

July 10, 2021 — A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high ...

July 10, 2021

The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

News | PET Imaging

FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate ...

June 28, 2021

GE Healthcare also recently announced Xeleris V, a new virtualized, flexible AI-powered solution that provides clinicians secure access to data from anywhere – helping them make personalized care decisions and treatment recommendations that are at the heart of precision health.

News | Nuclear Imaging

GE Healthcare Advances Precision Health & Theranostics With New Products & Solutions

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare ...

June 22, 2021

A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.

News | Prostate Cancer

PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen ...

June 21, 2021

A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.

News | PET Imaging

New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge

June 16, 2021 — A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases ...

June 16, 2021

SNMMI's Image of the Year is a detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame

News | PET Imaging

SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients

June 16, 2021 — The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET) ...

June 16, 2021

A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease — at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution, the imaging methodology combines position emission tomography (PET) with an external motion tracking device to create highly detailed images of the brain.

News | PET Imaging

New Super-resolution Technique Allows for More Detailed Brain Imaging

June 14, 2021 — A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease ...

June 14, 2021

Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.

News | PET-CT

Radiotracer Effective for Detection and Assessment of Lung Fibrosis

June 14, 2021 — Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) ...

June 14, 2021

Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

News | SPECT Imaging

Deep Learning with SPECT Accurately Predicts Major Adverse Cardiac Events

June 14, 2021 — An advanced artificial intelligence technique known as deep learning can predict major adverse cardiac ...

June 14, 2021

News | PET-CT

Canon Medical’s Digital PET/CT System Receives FDA Clearance

June 10, 2021 — Bringing the power of artificial intelligence (AI) to molecular imaging, Advanced intelligent Clear-IQ ...

June 10, 2021

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

News | PET Imaging

PET Imaging Adds Valuable Information to Brain Metastasis Monitoring

May 5, 2021 — For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable ...

May 05, 2021

#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress

April 16, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

April 16, 2021

CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.

News | PET Imaging

PET Imaging Tracer Effective for Diagnosing and Managing Rare CNS B-cell Lymphoma

December 14, 2020 — Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for ...

December 14, 2020

News | Nuclear Imaging

The Journal of Nuclear Medicine Celebrates 60 Years of Research

December 14, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of ...

December 14, 2020

Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nucle

News | PET Imaging

SNMMI Image of the Year Features Super-agers

July 16, 2020 — Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have been ...

July 16, 2020

Novel imaging agent provides foundation to inform treatment strategies

News | PET Imaging

Molecular Imaging Identifies Link Between Heart and Kidney Inflammation After Heart Attack

July 16, 2020 — Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of ...

July 16, 2020